Page 820 - Read Online

Page 14 of 15 Alqahtani et al. Hepatoma Res 2020;6:70 I http://dx.doi.org/10.20517/2394-5079.2020.65

Oncol 2020;38:108.
58. Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, et al. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-
fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs
2018;36:424-34.
59. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, et al. Derazantinib (ARQ 087) in advanced or inoperable
FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019;120:165-71.
60. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in
cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72-9.
61. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 2016;27:599-
608.
62. Abou-Alfa GK, Macarulla T, Javle M, Kelley RK, Lubner SJ, et al. ClarIDHy: a global, phase 3, randomized, double-blind study of
ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation.
Ann Oncol 2019;30:Abstract LBA 10_PR.
63. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human
cholangiocarcinoma. PLoS One 2011;6:e15640.
64. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, et al. Mouse model of intrahepatic cholangiocarcinoma validates
FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A 2013;110:19513-8.
65. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and
children. N Engl J Med 2018;378:731-9.
66. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82.
67. Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review
and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017;36:141-57.
68. Jensen LH. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opin Investig Drugs
2016;25:359-65.
69. Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic
review and meta-analysis. In Vivo 2020;34:479-88.
70. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract
cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-8.
71. Vogel A, Kasper S, Bitzer M, Block A, Sinn M, et al. PICCA study: panitumumab in combination with cisplatin/gemcitabine
chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer
2018;92:11-9.
72. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, et al. Evaluation of VEGF A expression and microvascular density as
prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007;33:1025-9.
73. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, et al. Transforming growth factor beta 1 stimulates vascular endothelial
growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003;63:1083-92.
74. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, et al. Efficacy and safety of gemcitabine, oxaliplatin, and
bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2
study. Lancet Oncol 2010;11:48-54.
75. Bréchon M, Dior M, Dréanic J, Brieau B, Guillaumot MA, et al. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus
oxaliplatin improves survival in advanced biliary tract cancers. Invest New Drugs 2018;36:156-62.
76. Valle J, Bai LY, Orlova R, Van Cutsem E, Adeva J, et al. Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine
(GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): a randomized, double-blind, phase
II study. J Clin Oncol 2020;38:Abstract 477.
77. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, et al. Ramucirumab plus pembrolizumab in patients with previously treated
advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 2018;23:1407-e136.
78. Yang XW, Li L, Hou GJ, Yan XZ, Xu QG, et al. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and
correlates negatively with surgical outcome. Oncotarget 2017;8:7710-21.
79. Dokduang H, Techasen A, Namwat N, Khuntikeo N, Pairojkul C, et al. STATs profiling reveals predominantly-activated STAT3 in
cholangiocarcinoma genesis and progression. J Hepatobiliary Pancreat Sci 2014;21:767-76.
80. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, et al. Prognostic significance of overexpression of c-Met oncoprotein in
cholangiocarcinoma. Br J Cancer 2011;105:131-8.
81. Pant S, Saleh M, Bendell J, Infante JR, Jones S, et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in
combination with gemcitabine in patients with solid tumors. Ann Oncol 2014;25:1416-21.
82. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, et al. Efficacy of pembrolizumab in patients with noncolorectal
high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-
10.
83. Silva VW, Askan G, Daniel TD, Lowery M, Klimstra DS, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair
deficiency. Chin Clin Oncol 2016;5:62.
84. Bang YJ, Ueno M, Malka D, Chung HC, Nagrial A, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from